Kinoshita N, Ghaedi K, Shimozawa N, Wanders R J, Matsuzono Y, Imanaka T, Okumoto K, Suzuki Y, Kondo N, Fujiki Y
Department of Biology, Kyushu University Faculty of Science, Fukuoka 812-8581, Japan.
J Biol Chem. 1998 Sep 11;273(37):24122-30. doi: 10.1074/jbc.273.37.24122.
We isolated peroxisome biogenesis-defective mutants from Chinese hamster ovary cells by the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method. Seven cell mutants, ZP116, ZP119, ZP160, ZP161, ZP162, ZP164, and ZP165, of 11 P9OH/UV-resistant cell clones showed cytosolic localization of catalase, a peroxisomal matrix enzyme, apparently indicating a defect of peroxisome biogenesis. By transfection of PEX cDNAs and cell fusion analysis, mutants ZP119 and ZP165 were found to belong to a novel complementation group (CG), distinct from earlier mutants. CG analysis by cell fusion with fibroblasts from patients with peroxisome biogenesis disorders such as Zellweger syndrome indicated that ZP119 and ZP165 were in the same CG as the most recently identified human CG-J. The peroxisomal matrix proteins examined, including PTS1 proteins as well as a PTS2 protein, 3-ketoacyl-CoA thiolase, were also found in the cytosol in ZP119 and ZP165. Furthermore, these mutants showed typical peroxisome assembly-defective phenotype such as severe loss of resistance to 12-(1'-pyrene)dodecanoic acid/UV treatment. Most strikingly, peroxisomal reminiscent vesicular structures, so-called peroxisomal ghosts noted in all CGs of earlier Chinese hamster ovary cell mutants as well as in eight CGs of patients' fibroblasts, were not discernible in ZP119 and ZP165, despite normal synthesis of peroxisomal membrane proteins. Accordingly, ZP119 and ZP165 are the first cell mutants defective in import of both soluble and membrane proteins, representing the 14th peroxisome-deficient CG in mammals, including humans.
我们通过9-(1'-芘基)壬醇/紫外线(P9OH/UV)方法从中国仓鼠卵巢细胞中分离出了过氧化物酶体生物发生缺陷型突变体。在11个P9OH/UV抗性细胞克隆中,7个细胞突变体ZP116、ZP119、ZP160、ZP161、ZP162、ZP164和ZP165显示出过氧化物酶体基质酶过氧化氢酶的胞质定位,这显然表明过氧化物酶体生物发生存在缺陷。通过转染PEX cDNA和细胞融合分析,发现突变体ZP119和ZP165属于一个新的互补群(CG),与早期的突变体不同。通过与过氧化物酶体生物发生障碍患者(如泽尔韦格综合征患者)的成纤维细胞进行细胞融合进行的CG分析表明,ZP119和ZP165与最近鉴定出的人类CG-J处于同一CG中。在ZP119和ZP165的胞质中也发现了所检测的过氧化物酶体基质蛋白,包括PTS1蛋白以及一种PTS2蛋白、3-酮酰基辅酶A硫解酶。此外,这些突变体表现出典型的过氧化物酶体组装缺陷表型,如对12-(1'-芘基)十二烷酸/UV处理的抗性严重丧失。最引人注目的是,尽管过氧化物酶体膜蛋白正常合成,但在ZP119和ZP165中却无法识别出在早期中国仓鼠卵巢细胞突变体的所有CG以及患者成纤维细胞的8个CG中都能看到的过氧化物酶体类似囊泡结构,即所谓的过氧化物酶体幽灵。因此,ZP119和ZP165是首批在可溶性蛋白和膜蛋白导入方面存在缺陷的细胞突变体,代表了包括人类在内的哺乳动物中的第14个过氧化物酶体缺陷CG。